Get started
Biodesix, Inc.Biodesix, Inc.Biodesix, Inc.

Biodesix, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

BDSX trade ideas

BDSX | Biodesix, Inc. Healthcare |Diagnostics & Research| NASDAQ🔄 Trend Reversal Alert: Potential Reversal Opportunities 📈📉 Technical Indicator: The Relative Strength Index (RSI) is showing a bullish divergence, where the stock's price is making equal lows and the RSI is forming higher lows. This suggests potential upward momentum and a trend reversal in the making. we can place a buy stop above neckline as shown in the analysis. 📊 Please note that trend reversals can be challenging to predict with certainty. Conduct comprehensive technical and fundamental analysis before making any investment decisions. Always use proper risk management techniques to protect your capital. Happy trading! 💹"
NASDAQ:BDSXLong
by shah_baz
Biodesix Inc 🧙Successfully secured additional liquidity and deferred principal repayments through February 2024 by closing a new $30.0 million term loan and retiring the prior term loan for $25.9 million; Total revenue of $28.9 million, an increase of 466% over first quarter 2020 and 7% over fourth quarter 2020; COVID-19 testing revenue of $23.2 million, an increase of 8% over fourth quarter 2020; Lung diagnostic revenue of $4.0 million, representing continued recovery and growth of 10% over first quarter 2020 and 8% over fourth quarter 2020; Services revenue of $1.7 million, an increase of 12% over first quarter 2020 and 12% decline over fourth quarter 2020; Gross profit of $10.6 million and gross margin percentage of 37%, both aligned with management expectations, primarily as a result of growth in COVID-19 testing; Operating expenses (excluding direct costs and expenses) of $16.2 million, which includes an investment in the planned expansion of our salesforce, increased 36% over first quarter 2020 and 8% over fourth quarter 2020; Non-cash stock compensation expense of $1.8 million, $0 and $3.7 million recognized during first quarter 2021, first quarter 2020 and fourth quarter 2020, respectively; and Net loss of $7.0 million, an improvement of 28% over first quarter of 2020 and a 54% increase over fourth quarter 2020. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:BDSXLong
by trading_as_bus
Biodesix, Inc. Breakout Targets Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
NASDAQ:BDSXLong
by DEXWireNews
1